BERLIN, Germany, April 15, 2021 / B3C newswire / -- ProBioGen announced today that Nouscom has activated a commercial product license to ProBioGen's innovative, cell-based vaccine platform AGE1.CR.pIX.
ProBioGen's AGE1.CR.pIX cell line was designed for large scale industrial production of various vaccines and viral vectors. The cell line was developed at ProBioGen from primary duck cells, is adapted to suspension-growth and comes with a specifically designed, chemically-defined medium and full documentation.
Elisa Scarselli, Chief Scientific Officer of Nouscom said: "Nouscom has recently announced regulatory approval to commence a Phase 1b clinical trial for its personalized cancer neoantigen-vaccine. ProBioGen's AGE1.CR.pIX technology and platform is well suited to enable the rapid manufacture of a component of our uniquely engineered viral vector vaccine."
Dr. Volker Sandig, ProBioGen's Chief Scientific Officer stated: "Nowadays, smart and cost-effective production processes for viral vectors are becoming increasingly important. I am enthusiastic about Nouscom's cutting-edge immunotherapies and I am pleased that we are able to provide them with our sophisticated production platform AGE1.CR.pIX; this shows once again its broad application possibilities."
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded
in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years, is privately owned, and based in Berlin, Germany.
Dr. Gabriele Schneider
Chief Business Officer
+49 (0)30 3229 35 100
Keywords: Cell Line; Cell Line; Technology; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Viruses; Vaccines; Viral Vaccines; Virus Cultivation; Biological Products; Productivity; Technology; Commerce; Germany
Published by B3C newswire